Anti-Factor Xa-Based Anticoagulation during Extracorporeal Membrane Oxygenation: Potential Problems and Possible...

Area of Science:

• Critical Care Medicine
• Hematology
• Pharmacology

Background:

• Extracorporeal membrane oxygenation (ECMO) requires careful anticoagulation monitoring.
• Unfractionated heparin (UFH) is commonly used for anticoagulation during ECMO.
• Anti-factor Xa activity is proposed as a gold standard for UFH monitoring in ECMO.

Purpose of the Study:

• To evaluate the limitations of anti-factor Xa assay for monitoring UFH in ECMO.
• To determine if anti-factor Xa can be used as the sole method for UFH monitoring in ECMO.
• To propose an improved strategy for UFH monitoring in ECMO patients.

Main Methods:

• Review of current literature on UFH monitoring in ECMO.
• Analysis of factors affecting anti-factor Xa assay accuracy.
• Comparison of anti-factor Xa with viscoelastic whole blood tests.

Main Results:

• Anti-factor Xa assay can be confounded by elevated bilirubin and free hemoglobin in ECMO patients.
• The assay may underestimate UFH effects with low antithrombin levels.
• Plasma-based anti-factor Xa does not account for platelet and fibrinogen contributions to clot stability.

Conclusions:

• Anti-factor Xa alone is insufficient for monitoring UFH in ECMO due to interfering factors and inability to assess clot dynamics.
• Thrombocytopenia, platelet dysfunction, and varying fibrinogen levels in ECMO patients complicate anti-factor Xa interpretation.
• Combining anti-factor Xa with whole blood viscoelastic tests provides a more comprehensive assessment of UFH's anticoagulant effect in ECMO.